Lasa Supergenerics Sets Q2 FY27 Results Meeting for November 14

Lasa Supergenerics Limited is scheduled to consider its Q2 FY27 results on 14 November 2026, 45 days after the September quarter ended, following a Q1 FY27 revenue decline of 93% year-on-year to ₹1.23 crore. The board meeting is significant because operations and profitability remain under pressure after a manufacturing-unit fire disrupted FY26.

When will Lasa Supergenerics announce Q2 FY27 results?

Lasa Supergenerics will consider and approve its financial results for the July-September 2026 quarter at a board meeting on Saturday, 14 November 2026. The company informed the National Stock Exchange on 4 November about the meeting. The stated reporting time is 12:08 PM Indian Standard Time.

The September quarter is Q2 of the financial year ending 31 March 2027. The planned release falls 45 days after the end of the quarter, matching the timing of the Q1 FY27 results, which were filed on 14 August 2026, also 45 days after the June quarter closed. Over the past eight quarters cited in the available data, the company has generally filed results between 44 and 59 days after quarter-end.

No Q2 FY27 revenue, profit or loss figures are provided in the available material. Investors will therefore need to rely on the exchange filing after the board meeting for the reported numbers, accompanying financial statements and any disclosures on operations.

What did Lasa Supergenerics report in Q1 FY27?

Lasa Supergenerics reported revenue from operations of ₹1.23 crore in Q1 FY27, compared with about ₹20.0 crore in the corresponding quarter a year earlier. The company recorded total income of ₹1.33 crore for the three months ended 30 June 2026, including ₹0.10 crore of other income.

The company posted a net loss of ₹3.58 crore for the quarter, or a loss per share of ₹0.71. While the business remained loss-making, the reported loss narrowed from ₹21.1 crore, or ₹4.22 per share, in Q1 FY26. The loss reduction came alongside a sharp contraction in revenue, so the quarter does not indicate a return to normal operating scale.

The Q1 numbers followed a March 2026 quarter in which sales were reported at negative ₹0.13 crore and net loss was ₹4.16 crore. On a sequential basis, Q1 revenue was higher than the March-quarter figure, while the quarterly net loss was lower. However, both periods reflected a business operating at a substantially reduced level from earlier periods.

Why are the Q2 results important for investors?

The Q2 update will provide a fresh measure of whether Lasa Supergenerics has improved production, customer supplies and revenue after the operational disruption disclosed for FY26. The company said a fire at one of its manufacturing facilities led to the closure and suspension of operations at the affected unit during that financial year.

According to the company’s FY26 performance review, the incident affected production capacity, sales and customer supplies. Fixed operating costs, restoration-related expenditure and other consequences of the interruption also hurt profitability. These issues provide the main context for the steep reduction in revenue reported during FY26 and the first quarter of FY27.

For the year ended 31 March 2026, revenue from operations fell to ₹25.14 crore from ₹142.45 crore in the preceding year. Lasa Supergenerics reported a full-year net loss of ₹34.09 crore, compared with a net loss of ₹14.76 crore in FY25. The company also reported a loss before interest, depreciation and tax of ₹7.17 crore for FY26, against a profit of ₹11.28 crore in the prior year.

How could the Q2 filing affect the company’s operating assessment?

The Q2 filing will help investors assess whether the June-quarter revenue level was temporary or whether the company continued to face restrictions in manufacturing and sales during July-September. Revenue progression, operating expenses, quarterly loss and management disclosures on restoration work will be central indicators because the available information does not provide a formal forecast or target for the September quarter.

The results are also relevant for customers and suppliers because FY26 disclosures identified production capacity and customer supplies as areas affected by the fire-related interruption. Any reported improvement in sales would need to be assessed alongside the cost of restarting or maintaining operations. Conversely, the available material does not support any conclusion on the Q2 outcome before the board considers the accounts.

For shareholders, the immediate factual backdrop is a large fall in annual revenue and continued quarterly losses. The source also notes that, over the past three years on average, earnings per share declined by 12% annually while the share price declined by 32% annually. That historical comparison highlights the gap between financial performance trends and market valuation, but it does not establish how the stock will react to the upcoming results.

Conclusion

Lasa Supergenerics is due to consider Q2 FY27 results on 14 November 2026 after a first quarter marked by ₹1.23 crore of revenue and a ₹3.58 crore net loss. The company’s recent results must be viewed against the FY26 manufacturing disruption, which contributed to a fall in annual revenue to ₹25.14 crore and a wider full-year loss.

The next item to watch is the board-approved Q2 filing, particularly its revenue from operations, net loss, earnings per share and disclosures on the affected manufacturing facility. The available source does not state a recovery timetable, production target or financial guidance for the September quarter.